TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or nonpregnant female, ages 18 to 70 years inclusive, at Screening Visit.~2. Biopsy-confirmed CD (intestinal histology showing villous atrophy).~3. Positive for human leukocyte antigen (HLA)-DQ2 or HLA-DQ2/DQ8 - results will be obtained at Screening if unknown or results are not available.~4. Self-reported to be on a GFD for at least 6 months prior to Screening and agree to continue GFD throughout study, with the exception of the oral gluten challenge.~Normal or negative celiac serology, at screening, defined as:~1. Measurable total serum immunoglobulin A (IgA) AND~2. Negative or weak positive tissue transglutaminase (tTG) IgA titer OR~3. If IgA deficient, defined by a serum IgA level of \< 3 mg/dL, negative or weak positive DGP- IgG titer.~   6. Vh:Cd ≥ 1.5 on screening biopsy.~   Key Exclusion Criteria:~  1. Positive for only HLA-DQ8.~  2. History of clinically confirmed immunoglobulin E (IgE)-mediated reaction and/or anaphylaxis to wheat (i.e., wheat allergy), barley or rye.~  3. Uncontrolled CD and/or active signs/symptoms of CD, in the opinion of the investigator.~  4. Untreated or active gastrointestinal disease such as peptic ulcer disease, esophagitis (Los Angeles Classification ≥ Grade C), irritable bowel syndrome, inflammatory bowel disease, or microscopic colitis.~  5. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior Dose 1, any dose of corticosteroids within 30 days of Day 1, or high dose inhaled corticosteroids \[\> 960 µg/day of beclomethasone dipropionate or equivalent\]) or other immunosuppressive agents.~  6. Presence or history of celiac-associated thyroid disease or Type 1 diabetes, regardless of current treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TIMP-GLIA (Type: EXPERIMENTAL): 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline administered intravenously on days 1 and 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Healthy males or females between 18 and 65 years of age (both inclusive) with body mass index between 19 and 30 kg/m2, inclusive, and body weight of not \<50 kg or \>95 kg, will be enrolled in this study.~Exclusion Criteria:~* Hematologic laboratory abnormalities (including leukocytosis \[defined as total leukocytes \>11,000/mcL\], leukopenia \[defined as total leukocytes \<4000/mcL\], or neutropenia \[defined as absolute neutrophil count \<1500/mcL\] or thrombocytopenia \[defined as platelet count of \<150,000/mcL\]) or other clinically significant abnormal laboratory evaluations.~* Lack of adequate hepatic or renal reserve.~* Any active systemic or immunologic disease or condition.~* History of biological growth factor exposure.~* Received live vaccination or exposure to communicable viral diseases within 4 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PF-06881894 (Type: EXPERIMENTAL): PF-06881894 6 mg SC
- US-approved Neulasta (Type: ACTIVE_COMPARATOR): US-approved Neulasta 6 mg SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insulin naïve subject (allowed are: previous short term insulin treatment up to 14 days; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)~* Current treatment: metformin monotherapy or metformin in any combination with an insulin secretagogue (sulfonylurea or glinide), DPP-4 inhibitor, alpha-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily maximal dose according to local labelling - alpha-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or maximum tolerated dose~* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis~* Body Mass Index (BMI) maximum 45.0 kg/m\^2~* Type 2 diabetes (diagnosed clinically) for at least 6 months~* Ability and willingness to adhere to the protocol including performance of self monitored plasma glucose (SMPG) profiles according to the protocol~Exclusion Criteria:~* Use within the last 3 months prior to Visit 1 of: thiazoledinediones (TZDs), exenatide or liraglutide~* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements \[for UK: adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods\]~* Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg 200 U/mL OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional Study With Ectoin Containing and/or Decongesting Nasal Spray in Patients With Rhinosinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with acute viral rhinosinusitis~* presence of common cold symptoms~Exclusion Criteria:~* contraindications in accordance with instructions for use~* acute bacterial rhinosinusitis~* chronic rhinosinusitis

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ectoin Rhinosinusitis Nasal Spray (Type: None): application of 1-2 sprays of SNS01 into each nostril several times a day
- Xylometazoline nasal spray (Type: None): 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
- Xylometazoline + Ectoin Nasal Spray (Type: None): Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Male and female heart failure patients with body weight \<160 kg, on standard therapy including a stable dose of furosemide 40-240 mg/day orally (p.o). or equivalent dose of loop diuretics, reduced systolic function (LVEF ≤ 45% measured within the past 6 months), BNP ≥ 100 pg/mL or NT-pro-BNP of ≥ 400 pg/mLNYHA Class II or III, and worsening symptoms, e.g. fatigue, dyspnea, breathlessness within 3 months~* Mild to moderate renal impairment~Exclusion criteria:~* Systolic blood pressure (SBP) \< 110 mm Hg at the time of randomization~* Administration of intravenous radiographic contrast agent within 72 hours prior to randomization or acute contrast-induced nephropathy at the time of randomization~* Current use of non-steroidal antiinflammatory drugs (NSAIDs)~* Current or planned (through the completion of study drug infusion) treatment with any i.v. therapies, including vasodilators (including nesiritide), positive inotropic agents, vasopressors, levosimendan, or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device).~* Clinically significant hepatic impairment defined as hepatic encephalopathy of any degree or total bilirubin \> 50 μmol/l (3 mg/dl) or, if patient is not on warfarin therapy, INR \> 2.0 (or Prothrombin Time \> 2 \* ULN)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RLX030 (Type: EXPERIMENTAL): RLX030 as intravenous infusion for 24 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo as intravenous infusion for 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for donor lung:~1. Recipient to undergo a single or bilateral Lung Transplantation~2. Last donor PaO2/FiO2 ≤ 300mmHg~3. Poor oxygenation and/or poor lung compliance is the primary reason for unsuitability~4. Absence of pneumonia, persistent purulent secretion on bronchoscopy or significant mechanical trauma~Exclusion Criteria:~1. Infection~2. Aspiration~3. Significant mechanical lung injury - contusion~4. Infectious diseases : HIV, Hepatitis B and C, HTLV \& Syphilis~5. Malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVLP Group (Type: EXPERIMENTAL): EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male or female between, and including, 6-16 weeks (42 to 118 days) of age at the time of the first vaccination, free of obvious health problems and with written informed consent obtained from the parent/guardian of the subject.~Exclusion Criteria:~* use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the entire study period.~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.~* Previous vaccinations against diseases which are targeted by the vaccines used in the study.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women aged ≥ 20 and \< 75 years at the time of consent;~* Estrogen receptor positive and/or progesterone receptors positive;~* HER2-negative~* Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane~Exclusion Criteria:~* Radiation therapy or immuno therapy within 14 days before the first dose of investigational product;~* Chemotherapy, biological medicines, other pharmacotherapy or major surgery within 21 days before the first dose of the investigational product;~* Prior chemotherapies of ≥ 3 regimens for advanced or recurrent breast cancer;~* Ongoing treatment with other investigational product

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- KHK2375 PO and Exemestane PO (Type: EXPERIMENTAL): KHK2375 and Exemestane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation~2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea.~3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of \>7.0% and \< or = 10% at Visit 1 (screening)~4. Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study)~5. Age \> or =18 years at Visit 1 (screening)~6. BMI \< or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)~Exclusion criteria:~1. Patients with poorly controlled hyperglycemia~2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy~3. MI, stroke, or TIA within 3 months prior to obtaining informed consent~4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias~6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): Patients receive BI 10773 low dose daily
- BI 10773 high dose (Type: EXPERIMENTAL): Patients receive BI 10773 high dose daily
- placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo to match BI 10773 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients are eligible to be included in the study if they meet all of the following criteria:~* are ≥ 18 years of age~* have been diagnosed with STEMI or NSTEMI during the index hospitalization~* be treated with a P2Y12 receptor inhibitor at the time of enrollment~* have U.S. based health insurance coverage with prescription drug benefit~* have been fully informed and are able to provide written consent for longitudinal follow-up~Exclusion Criteria:~Patients are excluded if they meet any of the following criteria:~* have a history of prior intracranial hemorrhage~* have any contraindications to P2Y12 receptor inhibitor therapy at discharge~* involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.~* have a life expectancy of less than one year~* have plans to move outside the US in the next year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Copayment Intervention Arm (Type: EXPERIMENTAL): Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
- Usual Care Arm (Type: NO_INTERVENTION): For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient must be diagnosed with any of the approved epilepsy indications for CBZ that include: Partial seizures with complex symptomatology (psychomotor, temporal lobe); Generalized tonic clonic seizures (grand mal); Mixed seizure patterns that include one of the above; Other partial or generalized seizures.~* Patient must be receiving a stable dose of oral CBZ (tablet or capsule formulation) for a minimum of 14 days prior to Day -28.~* Patient must be receiving a constant dose of all other concomitant medications / device (including AEDs, Vagal Nerve Stimulator (VNS), OTC medications, and herbal supplements) that may not interfere with the metabolism of CBZ for a minimum of 14 days prior to Day -28. No change in baseline AEDs are expected during the treatment period.~* The patient must be able to comply with maintaining an accurate epilepsy medication dosing diary and seizure diary.~* If female: Patient is not of childbearing potential.~* If childbearing potential: Must have a negative serum pregnancy test at Day -28 and a negative serum pregnancy test on Day -1; Must comply with a method of birth control acceptable to the investigator (with the exception of hormone based contraceptives which are contraindicated with the use of CBZ).~Exclusion Criteria:~* Patient is taking a daily oral dose of CBZ greater than 2000 mg per day.~* Patient is being treated with hormone based therapy for birth control.~* Patient has a QTc interval value that is greater than 450 msec.~* Patient has a screening ALT, AST or bilirubin \> 3 times the upper limit of normal.~* Patients with CLCR \< 30 mL/min or with a renal disorder (i.e. nephrotic syndrome, patients on hemodialysis or peritoneal dialysis or being considered for peritoneal or hemodialysis).~* Patient is receiving oral CBZ for absence seizures.~* Patient has had an episode of status epilepticus within 30 days of screening.~* Patient has a history of severe or serious adverse reactions to CBZ (e.g. aplastic anemia, agranulocytosis).~* Patient has been diagnosed with narrow angle glaucoma.~* Patient weighs less than 50 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Gun Study: Can Safety Videos Mitigate Interest in Guns in Children?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8-12 yrs~* No prior participation in the study~* Able to schedule participation with a known peer (8-12yo).~Exclusion Criteria:~* Younger than 8 yrs old~* Older than 12 yrs old~* Prior study participation~* Could not schedule participation with a known peer (8-12yo)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Gun safety vid x Movie clip - guns present (Type: EXPERIMENTAL): Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.
- Gun safety vid x Movie clip - guns absent (Type: ACTIVE_COMPARATOR): Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure with the guns edited out.
- Seatbelt safety video x Movie clip - guns present (Type: ACTIVE_COMPARATOR): Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.
- Seatbelt safety video x Movie clip - guns absent (Type: ACTIVE_COMPARATOR): Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete